🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

The sexually transmitted infection are escalating worldwide, with estimates suggesting in excess of 82 million new cases per year. Notably increased rates are seen in the African continent and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the face of rising global incidence, increasing antimicrobial resistance and the very limited available drugs at this time.”

Health officials are deeply concerned about the surge in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This STI can lead to major issues, including infertility. Researchers hope that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Results and Worldwide Availability

Based on results detailed in a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This puts it on an equal footing with the current standard treatment, which uses an injection and a pill. The research enrolled over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Clinicians on the front lines have expressed hope. Access to a easy-to-administer therapy like this is seen as a "critical tool" for managing the epidemic. This is viewed as vital to lessen the impact of the illness for individuals and to halt the transmission of untreatable gonorrhoea worldwide.